Clinical trials, ototoxicity grading scales and the audiologist’s role in therapeutic decision making

King, Kelly A.; Brewer, Carmen C.

doi:10.1080/14992027.2017.1417644

Cited by 33 publications

(33 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Otherwise, any change in hearing may be misrepresented as being related to ototoxicity caused by treatment when it may be conductive in nature. 27,28 When testing children less than 7 months of age, it is necessary to do so using a 1-kHz probe tone. Literature has shown that this probe tone frequency is more sensitive to middle ear dysfunction in neonates and infants (up to 6 months of age) compared with a 226-Hz probe tone.…”

Section: Immittance Testingmentioning

confidence: 99%

“…But it is also important to convey to the physician the impact the hearing loss is having on the patient's communication ability. 27 The ASHA guidelines define a significant change in hearing compared with baseline as follows:…”

Section: What Constitutes a Significant Change And The Use Of Gradingmentioning

confidence: 99%

“…6 By the time hearing loss is detected within the standard frequency range, the patient already may be experiencing communication difficulties. 27 Animal research and clinical trials on humans administered ototoxic drugs have shown that damage to the cochlea initially occurs in the basal end of the cochlea which causes hearing loss to progress from high to low frequencies. 7 Knight et al completed baseline and follow-up standard frequency and EHF testing on 17 children as part of a study comparing standard frequency audiometry, EHF audiometry, and DPOAEs.…”

mentioning

confidence: 99%

“…The results showed a clear advantage to testing in the EHF range as 86.5% of the ears tested showed a change in HLs in the EHF range compared with only 34.6% for the standard frequency range. 27 As part of the same study, a third protocol to identify a hearing loss was utilized and referred In addition, room noise using OtoID is measured must before presentation of each tone as extra measure that noise levels in room are well controlled. Using insert earphones for collecting distortion-product otoacoustic emissions, all f2 frequencies can be used.…”

mentioning

confidence: 99%

“…In the pediatric population, for example, which is already prone to otitis media with effusion, the use of immunosuppressive chemotherapeutic drugs and/or cranial radiation places them at greater risk for this condition. 27,28 Older children and adults also may develop otitis media with effusion if treated similarly.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Monitoring Protocols for Cochlear Toxicity

Lord¹

2019

Semin Hear

View full text Add to dashboard Cite

The need for monitoring hearing and auditory function during drug therapy and other treatments that have the potential to cause hearing loss is well documented. Besides the main purpose of ototoxic monitoring, which is to provide feedback to the attending physician about the effects the treatment is having on the auditory system, it is also helpful in setting expectations for the patient and his/her family about the communication issues that may result from the drug therapy. This article will review tests available to an audiologist, both subjective and objective, that can be used to effectively monitor hearing levels and auditory function during treatment. Published guidelines and various ototoxic monitoring protocols are reviewed regarding tests administered, what constitutes a significant change in test results and how these findings are reported, and the impact significant changes may have on the course of treatment. Test protocols from different institutions are compared for both similarities and contrasts. Effective scheduling and test location are key to a successful monitoring program. Finally, the need to streamline ototoxic monitoring of hearing and auditory function to reduce test time and make it less stressful and tiresome on the patient will be considered.

show abstract

Section: Immittance Testingmentioning

confidence: 99%

Section: What Constitutes a Significant Change And The Use Of Gradingmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Monitoring Protocols for Cochlear Toxicity

Lord¹

2019

Semin Hear

View full text Add to dashboard Cite

show abstract

The impact of chemotherapy-induced inner ear damage on quality of life in cancer survivors: a qualitative study

et al. 2021

View full text Add to dashboard Cite

Purpose This study aimed to explore the burden of inner ear damage (ototoxicity) on adults living with and beyond cancer treated with chemotherapy and the impact on their quality of life (QoL). Furthermore, this study aimed to explore patient awareness surrounding chemotherapy-induced inner ear damage, known as ototoxicity, and assess what support they had been offered. Methods Participants were adults who had undergone chemotherapy, recruited from cancer clinics, charities and social media. Using semi-structured interviews and fieldnotes, an inductive thematic analysis was used to develop key themes surrounding this topic. Results Twenty participants from the UK were interviewed. Two key themes were developed from the thematic analysis, cancer-related QoL and ototoxicity-related QoL, with each one including 5 subthemes. Subthemes consisted of impact of ototoxicity, hearing, tinnitus, clinical experience, audiological assessments, and impact of treatment, cancer and chemotherapy, other toxicities, information and patient reflections. Conclusions Ototoxicity can have a negative impact on QoL, specifically on social life and the fear of hearing loss and/or tinnitus worsening. There are opportunities for increased awareness by patients and clinicians, including improved information sources, and hearing monitoring not only for those undergoing platinum-based chemotherapy but many others surviving after treatment for cancer. Implications for Cancer Survivors Better monitoring of hearing and information about ototoxicity during chemotherapy could potentially reduce the fear of the symptoms of ototoxicity worsening. Furthermore, hearing monitoring would facilitate the detection of hearing loss at early stages of survivorship, which would facilitate earlier access to clinical interventions and longer term counselling.

show abstract